Ignite Creation Date:
2024-05-06 @ 12:20 PM
Last Modification Date:
2024-10-26 @ 12:57 PM
Study NCT ID:
NCT03730012
Status:
COMPLETED
Last Update Posted:
2022-08-15
First Post:
2018-11-01
Brief Title:
A Study of ASP2215 Gilteritinib Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase FLT3 Mutated Acute Myeloid Leukemia AML
Sponsor:
Astellas Pharma Global Development Inc
Organization:
Astellas Pharma Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-06-19
Start Date Type:
ACTUAL
Primary Completion Date:
2021-05-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-06-15
Completion Date Type:
ACTUAL
First Submit Date:
2018-11-01
First Submit QC Date:
November 1 2018
Study First Post Date:
2018-11-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2022-06-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-08-11
Last Update Post Date:
2022-08-15
Last Update Post Date Type:
ACTUAL